平凡Stone2015-03-21 10:02
报告作者:Jacob Plieth 报告出处:Vantage
相关股票:$ Juno Therapeutics (JUNO)$ $Kite Pharma(KITE)$
To say that recent progress in CAR-T therapies was greeted
with market enthusiasm last year could be the understatement
of 2014. And as 2015 gets under way this a...查看全文
邦妮邦德2015-03-20 18:46
AACR2015会议相关受益医药股:
$Ariad Pharmaceuticals(ARIA)$ ,$ Juno Therapeutics (JUNO)$ ,$Kite Pharma(KITE)$ ,$新基(CELG)$ ,$BLUEBIRD BIO INC(BLUE)$ , $伊希斯医药品(ISIS)$ ,$阿斯利康(AZN)$ ,$ZIOPHARM Oncology(ZIOP)$ 等。
本人持有aria正股,celg call,isis正股,azn正股...查看全文
淡投2015-03-20 00:49
AACR abstract title suggests signal of activity in solid tumors, specifically mesothelin expressing cancers $ Juno Therapeutics (JUNO)$ $Kite Pharma(KITE)$ $Bellicum Pharmaceuticals (BLCM)$查看全文
姿势混子2015-03-20 00:14
$ Juno Therapeutics (JUNO)$ $BLUEBIRD BIO INC(BLUE)$ $Kite Pharma(KITE)$
本交易日,两支生物科技类股票Juno Therapeutics(JUNO)和Kite Pharma(KITE)突然爆发,两股涨幅均超过10%。两支股票的概念都是癌症免疫疗法,这是一种让癌症患者免于化疗而利用药物选择性杀死癌细胞的治愈癌症的疗法...查看全文
淡投2015-03-03 02:43
$Kite Pharma(KITE)$ doubles down on crucial NCI partnership, expands work on CAR-T/TCRs查看全文
为进一步推动其不断增长的细胞治疗业务,吉利德科学公司近日表示计划收购Tmunity Therapeutics,这是一家试图开发更新、更好CAR-T疗法的私营生物技术公司。 吉利德目前拥有Yescarta和Tecartus两款CAR-T疗法,于2017年... 网页链接
复星医药5月13日晚间公告称,其控股子公司复星医药产业与Kite Pharma签订合同,双方拟分别出资不超过2500万美元对复星凯特进行同比例增资,认缴复星凯特等值新增注册资本。增资后,复星医药产业对复星凯特的持股比例保持不变(仍为50%),复... 网页链接
智通财经APP讯,复星医药(600196.SH)公告,2022年5月13日,公司控股子公司复星医药产业与Kite Pharma 签订《合营合同之修正案(十一)》,双方拟分别出资不超过2500万美元(或不超过等值于2500万美元的人民币)对复星凯特进行同比例增资,认... 网页链接
智通财经APP讯,复星医药(02196)公布,2022 年 4 月 1 日,控股子公司复星医药产业与 Kite Pharma 签订《合营合同之修正案(十)》,复星医药产业与 Kite Pharma 拟根据各自所持复星凯特股权比例对其进行增资,其中:复星医药产业拟以等值... 网页链接
智通财经APP讯,复星医药(600196.SH)公告,2022年4月1日,公司控股子公司复星医药产业与Kite Pharma 签订《合营合同之修正案(十)》,复星医药产业与Kite Pharma 拟根据各自所持复星凯特股权比例对其进行增资,其中:复星医药产业拟以等... 网页链接
阿基仑赛系从Kite Pharma 引进的Yescarta,公司仅用一年多时间完成桥接试验并提交NDA.2021 年6 月22 日,阿基仑赛正式国内获批上市。全球共有5 款CAR-T 细胞疗法获批上市,预计2030 年市场规模可达218 亿美元。 阿基仑赛成为国内首个上市C... 网页链接
6月22日晚间,国家药监局(NMPA)官网公示显示,复星凯特生物科技有限公司(简称“复星凯特”)CAR-T细胞治疗产品益基利仑赛注射液(代号:FKC876)已正式获批,这意味着中国迎来首款获批上市的CAR-T细胞治疗产品。 根据复星凯特公布的消息,上... 网页链接
$Kite Pharma(KITE)$ UPLOAD [Cover] - SEC-generated letter Filed: 2017-10-12 AccNo: 0000000000-17-036237 Size: 35 KB 网页链接
$Kite Pharma(KITE)$ 15-12B - Securities registration termination [Section 12(b)] Filed: 2017-10-13 AccNo: 0001193125-17-309956 Size: 9 KB 网页链接
$Kite Pharma(KITE)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2017-10-05 AccNo: 0001140361-17-037720 Size: 66 KB 网页链接
$Kite Pharma(KITE)$ S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments Filed: 2017-10-03 AccNo: 0001193125-17-302404 Size: 19 KB 网页链接
$Kite Pharma(KITE)$ S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments Filed: 2017-10-03 AccNo: 0001193125-17-302383 Size: 19 KB 网页链接
$Kite Pharma(KITE)$ S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments Filed: 2017-10-03 AccNo: 0001193125-17-302355 Size: 19 KB 网页链接
$Kite Pharma(KITE)$ S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments Filed: 2017-10-03 AccNo: 0001193125-17-302342 Size: 19 KB 网页链接
$Kite Pharma(KITE)$ POSASR - Post-effective Amendment to an automatic shelf registration statement Filed: 2017-10-03 AccNo: 0001193125-17-302338 Size: 19 KB 网页链接
$Kite Pharma(KITE)$ S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments Filed: 2017-10-03 AccNo: 0001193125-17-302383 Size: 19 KB 网页链接
$Kite Pharma(KITE)$ S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments Filed: 2017-10-03 AccNo: 0001193125-17-302383 Size: 19 KB 网页链接